Clinical significance of the antibody to the hepatitis B virus-associated polymerized human albumin receptor in liver diseases

概要

論文の詳細を見る
An enzyme-linked immunosorbent assay (ELISA) was used as an inhibition test to detect the antibody (anti-pAR) to the hepatitis B virus (HBV) -associated polymerized human serum albumin (pHSA) receptor (HBV-pAR) in 476 subjects. Anti-pAR was detected with high frequency in liver disease patients with anti-HBs and in those with advanced liver disease. It was also detected in 2 HBsAg-positive chronic active hepatitis (CAH), 1 HBsAg-positive liver cirrhosis and 2 HBsAg-, anti-HBs-negative CAH patients with high sGPT levels. During acute exacerbation of 2 HBsAg CAHs, HBV-pAR activity reached its peak 1-2 months before and after to the peak of sGPT level, and the anti-pAR titer was parallel to the peak of sGPT level. The assay of anti-pAR appears to have value in estimating the severity of the liver disease.